



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov



Bib Data Sheet

CONFIRMATION NO. 5212

SERIAL NUMBER 10/088,885	FILING DATE 03/22/2002 RULE	CLASS 514	GROUP ART UNIT 1624	ATTORNEY DOCKET NO. Le A 33 914
-----------------------------	---------------------------------------	--------------	------------------------	------------------------------------

APPLICANTS

Thomas Fahrig, Gladbach, GERMANY;

Helmut Haning, Milford, CT;

Bernd Riedl, Leverkusen, GERMANY; Gabriele Braunlich, Leverkusen, GERMANY;

Rolf Henning, Leverkusen, GERMANY;

** CONTINUING DATA *****

This application is a 371 of PCT/EP00/08890 09/12/2000

** FOREIGN APPLICATIONS *****

UNITED KINGDOM 9922710.0 09/24/1999

Foreign Priority claimed 35 USC 119 (a-d) conditions met Verified and Acknowledged	<input checked="" type="checkbox"/> yes <input type="checkbox"/> no <input checked="" type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after Allowance Examiner's Signature: <i>[Signature]</i> Initials: <i>[Initials]</i>	STATE OR COUNTRY GERMANY	SHEETS DRAWING 1	TOTAL CLAIMS 8	INDEPENDENT CLAIMS 2
--	---	------------------------------------	----------------------------	--------------------------	--------------------------------

ADDRESS

Jeffrey M Greenman
Vice President, Patents and Licensing
Bayer Corporation
400 Morgan Lane
West Haven , CT
06516

TITLE

Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis

FILING FEE RECEIVED 974	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:	<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees (Filing) <input type="checkbox"/> 1.17 Fees (Processing Ext. of time) <input type="checkbox"/> 1.18 Fees (Issue) <input type="checkbox"/> Other <input type="checkbox"/> Credit
-----------------------------------	---	---